Moreover, pharmacological targeting of PML with arsenic trioxide, an FDA-approved drug used as first-line therapy in leukemia, reactivates p53 and delays ccRCC tumor growth. The gene discussed is TP53; the disease is nonpapillary renal cell carcinoma.